Product Description
EZN-4176 is a third-generation antisense oligonucleotide that binds to the hinge region (exon 4) of AR mRNA resulting in full-length AR mRNA degradation and decreased AR protein expression. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/24169353/)
Mechanisms of Action: AR Antagonist
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Enzon
Company Location: CRANFORD NJ 07016
Company CEO: Richard L. Feinstein
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Prostate Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01337518 |
EZN-4176-01 | P1 |
Suspended |
Prostate Cancer |
2013-12-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|